Loading...

Media is loading
 

Date of Award

Spring 2020

Degree Name

Master of Medical Science (Physician Assistant)

Department

Physician Assistant; College of Health Sciences

First Advisor

Renee Langstaff, MSPAS, PA-C

Abstract

Coronary artery disease (CAD) is the leading cause of death in both sexes, accounting for a third of all deaths in developed countries. One of the mainstays in treatment in both CAD and peripheral arterial disease (PAD) is the prevention of thrombus formation using antiplatelets, with aspirin as the drug of choice. Currently, rivaroxaban, a direct factor Xa inhibitor, is being studied in patients with CAD and PAD. This review addresses the efficacy of rivaroxaban, with or without aspirin, in the prevention of major adverse cardiovascular events, in adults with CAD and PAD, compared to standard of care, aspirin.

Additional Files

References page for poster.pdf (63 kB)
Reference list

PICO Poster.pdf (11395 kB)
PDF of poster

Share

COinS
 

Efficacy of Rivaroxaban (Xarelto) ± Aspirin in the Prevention of Major Adverse Cardiovascular Events

Coronary artery disease (CAD) is the leading cause of death in both sexes, accounting for a third of all deaths in developed countries. One of the mainstays in treatment in both CAD and peripheral arterial disease (PAD) is the prevention of thrombus formation using antiplatelets, with aspirin as the drug of choice. Currently, rivaroxaban, a direct factor Xa inhibitor, is being studied in patients with CAD and PAD. This review addresses the efficacy of rivaroxaban, with or without aspirin, in the prevention of major adverse cardiovascular events, in adults with CAD and PAD, compared to standard of care, aspirin.